Biotech Values

[poorgradstudent]

On/Off/Rheostat:

I've absolutely no doubt you can do it in preclinical.

But i think the ability to control the in vivo setting in the preclinical model is key. In the clinical setting, the variables increase and so does the complexity.

Disease burden, amount of CAR-T that is manufactured and injected, and the persistence of the CAR-T in the circulation all become variables that will have to be juggled.

Great that people are working on it, but at this stage I don't see it being a meaningful differentiator for one company over another.

I guess I'm just a curmudgeon on this one.